GlassScriptPhysician profile
Rene A Paez
NPI 1821106527
$2,256.74
in general payments reported to CMS, 2019-2025
26 companies · $534 in 2025
The $534 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $45.02 · 2021: $146 · 2022: $286 · 2023: $306 · 2024: $353 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.87 | 2019-2024 | |
| Hologic Sales and Service, LLC | $332.20 | 2019-2025 | Novasure, Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $230.81 | 2022-2025 | |
| Intuitive Surgical, INC. | $209.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.96 | 2019-2025 | |
| Pfizer INC. | $121.74 | 2023-2025 | |
| Astellas Pharma US INC | $114.07 | 2023-2025 | Veozah |
| Medicem INC. | $111.87 | 2021 | |
| Coopersurgical, INC. | $106.87 | 2022-2024 | Paragard T 380a, Endosee, Paragard T 380a |
| Daiichi Sankyo INC. | $83.49 | 2019-2022 | |
| Biogen, INC. | $76.93 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $54.69 | 2023-2025 | Myfembree |
| Innovation Technologies INC | $43.63 | 2025 | Irrisept |
| Myovant Sciences INC. | $43.43 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $26.69 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $25.21 | 2022 | |
| Davol INC. | $23.75 | 2019 | |
| Millicent US INC | $20.92 | 2025 | Intrarosa, Femlyv |
| Organon LLC | $19.74 | 2024 | |
| Smith+Nephew, INC. | $18.39 | 2024 | Stravix |
| Baxter Healthcare | $18.19 | 2025 | Perclot |
| Scynexis, INC. | $15.13 | 2022 | |
| Mission Pharmacal Company | $13.57 | 2019 | |
| Therapeuticsmd, INC. | $13.28 | 2019 | |
| Allergan, INC. | $11.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Paez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.